Stock CYTH CYCLO THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Cyclo Therapeutics, Inc.

Equities

CYTH

US23254X2018

Market Closed - Nasdaq
Other stock markets
 04:30:00 2024-05-03 pm EDT 		5-day change 1st Jan Change
1.51 USD +2.72% Intraday chart for Cyclo Therapeutics, Inc. +19.84% -5.03%
May. 01 HC Wainwright Starts Cyclo Therapeutics With Buy Rating, $3 Price Target MT
Mar. 18 Cyclo Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Cyclo Therapeutics : Corporate Presentation
PU
HC Wainwright Starts Cyclo Therapeutics With Buy Rating, $3 Price Target
MT
Cyclo Therapeutics : Corporate Presentation
PU
Cyclo Therapeutics : Corporate Presentation
PU
Cyclo Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
BU
Cyclo Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Cyclo Therapeutics Announces Issuance of U.S. Patent Covering the Use of Trappsol Cyclo for the Treatment of Alzheimer's Disease
AQ
Cyclo Therapeutics Granted Patent Covering Use of Trappsol Cyclo for Alzheimer's Disease
MT
Cyclo Therapeutics Announces Issuance of U.S. Patent Covering the Use of Trappsol® Cyclo™ for the Treatment of Alzheimer’s Disease
BU
Cyclo Therapeutics Announces Allowance of Patent Application for Treatment of Alzheimer's Disease from the U.S. Patent and Trademark Office
AQ
Cyclo Therapeutics Announces Allowance of Patent Application for Treatment of Alzheimer’s Disease from the U.S. Patent and Trademark Office
BU
Cyclo Therapeutics : Modification to Rights of Security Holders - Form 8-K
PU
Cyclo Therapeutics, Applied Molecular Transport Complete Merger
MT
Cyclo Therapeutics, Inc. Completes Merger with Applied Molecular Transport Inc.
BU
Cyclo Therapeutics, Inc. Appoints Shawn Cross to the Board of Directors
CI
Cyclo Therapeutics, Inc. completed the acquisition of Applied Molecular Transport Inc. from a group of shareholders for $10.2 million.
CI
Cyclo Therapeutics : Scientific Presentation
PU
Cyclo Therapeutics Announces Positive Outcome from Type C Meeting with the U.S. FDA Discussing Trappsol® Cyclo™ Clinical Program for the Treatment of Niemann-Pick Disease Type C1
BU
Cyclo Therapeutics, Inc. Announces Positive Outcome from Type C Meeting with U.S. FDA Discussing Trappsol Cyclo Clinical Program for Treatment of Niemann-Pick Disease Type C1
CI
Cyclo Therapeutics : Material Event - Form 8-K
PU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CYTH Stock
  4. News Cyclo Therapeutics, Inc.